Printer Friendly

ABBOTT TO ACQUIRE HEMATOLOGY BUSINESS

 ABBOTT TO ACQUIRE HEMATOLOGY BUSINESS
 ABBOTT PARK, Ill., Dec. 3 /PRNewswire/ -- Abbott Laboratories


(NYSE: ABT) announced today that it has signed an agreement to acquire Sequoia-Turner Corporation which has been doing business under the name Unipath Company.
 Sequoia-Turner is a major supplier of a broad line of hematology instruments and reagents for hospital and alternate site laboratories.
 Sequoia-Turner, which is a wholly owned subsidiary of Unilever United States, Inc., is located in Mountain View, Calif.
 The acquisition will provide Abbott with an entry into the nearly $1 billion worldwide hematology segment of the diagnostics marketplace, a segment that Abbott does not currently serve.
 "Sequoia-Turner has a high-quality and well-respected product line and a strong pipeline," said David A. Thompson, senior vice president, diagnostics operations. "This agreement will allow us to provide additional product families for our customers and positions us well in an important segment of the diagnostics market in which we do not currently participate."
 Hematology is the measurement of various constituents of whole blood including red and white blood cells and platelets. The Sequoia-Turner state-of-the-art instruments and reagents aid in the rapid and highly reliable diagnosis of several clinically important disease states. Sequoia-Turner has a complete line of hematology instruments, ranging from the Cell-Dyn 400, a manual, low volume analyzer to the Cell-Dyn 3000 SL, a fully automated high volume instrument which measures 22 parameters.
 Financial terms of the agreement were not disclosed.
 Abbott Laboratories is a worldwide manufacturer of health care products employing 45,000 people. In 1990, the company's sales and net earnings were $6.2 billion and $966 million, respectively, with earnings per share of $2.22.
 -0- 12/3/91
 /CONTACT: Catherine Babington of Abbott Laboratories, 708-937-8943, or John Gould of Unilever United States, 212-906-4694/
 (ABT) CO: Abbott Laboratories ST: Illinois IN: MTC SU: TNM


CK -- NY030 -- 8688 12/03/91 10:40 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 3, 1991
Words:310
Previous Article:STATE REP. JOSEPH R. PITTS: TAX RELIEF LONG OVERDUE
Next Article:ATLANTA REGAINS NO. 1 POSITION AS BEST BUSINESS LOCATION IN 1991 CUSHMAN & WAKEFIELD MONITOR
Topics:


Related Articles
TOA MEDICAL ELECTRONICS, LTD. AGREES IN PRINCIPLE TO ACQUIRE HEMATOLOGY SALES AND SUPPORT UNIT OF BAXTER DIAGNOSTICS INC.
ABBOTT LABORATORIES ACQUIRES CONTROL OF MEDISENSE, INC.
Applied Imaging Corp. Names Carl Hull Vice President of Worldwide Marketing
Abbott Laboratories to Acquire International Murex Technologies Corporation For $234 Million or $13 Per Share
Abbott Laboratories Acquisition of Perclose, Inc. Receives Antitrust Clearance.
Abbott Laboratories Announces Acquisition of Perclose, Inc. and Agreement With Biocompatibles International Plc.
SpectRx, Inc. Announces Appointment to its Board of Directors Of Chris Monahan, Retired Abbott Laboratories Executive.
Abbott Acquires Spine Next, S.A., a Manufacturer of Non-Fusion Spinal Implant Devices.
Judge Rules Gengraf Does Not Infringe Novartis Patent.
Abbott Acquires Spine Next, S.A., a Manufacturer of Non-Fusion Spinal Implant Devices.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters